A record £3 billion ($4.1 billion) has been raised by the UK biotech and life science sector in the first three quarters of 2021, according to new data released today the BioIndustry Association (BIA) and Clarivate.
With £576 million raised between June and the end of August, fundraising in 2021 has already surpassed the previous record year of 2020, when £2.8 billion was raised, with another three months of the year left to go.
The report shows in the past quarter, two companies secured over £100 million each and a further three raised over £20 million each in venture funding to finance their growth. These deals, led by experienced US and Korean investors, show the world-leading reputation of UK biotech and life science companies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze